Health, Inequality and Social Justice, International relations

US Finally Offers to Send Vaccines Abroad, But Lack of Global Plan Leaves Poorer Nations in Crisis

Jun 10 2021

By Amy Goodman* – Democracy Now!

Amy Goodman interviews Jeffrey Sachs and Fatima Hassan, Part two

Context and interview to Jeffrey Sachs, Director of the Center for Sustainable Development at Columbia University and president of the U.N. Sustainable Development Solutions Network.

The Biden administration on Thursday announced that the U.S. will donate 25 million surplus doses of COVID-19 vaccines to developing countries, pledging to donate a total of 80 million doses by July.

Economist Jeffrey Sachs says rich countries have enough production capacity to speed up vaccine distribution and immunize the whole world within the next year. “There’s massive supply, but there’s no plan for allocation,” he says.

We also speak with South African health justice activist Fatima Hassan, who says the global vaccine imbalance comes down to political will. “Even now countries are still sitting around a table and talking and having long conversations instead of figuring out an urgent way to ramp up manufacturing, scale up production and get as many doses to as many people as possible all over the world.”

AMY GOODMAN: The Biden administration announced plans to send 25 million COVID vaccine doses to dozens of countries in Latin America, Africa and Asia, where COVID cases continue to surge. The majority of the vaccines will be distributed through COVAX, a program backed by the World Health Organization. National security adviser Jake Sullivan said the administration plans to send a total of 80 million doses by the end of the month.

JAKE SULLIVAN: We’re sharing them in a wide range of countries within Latin America and the Caribbean, South and Southeast Asia, and across Africa in coordination with the African Union. This includes prioritizing our neighbors here in our hemisphere, including countries like Guatemala and Colombia, Peru and Ecuador and many others.

AMY GOODMAN: The Biden administration’s announcement comes just before the president heads to Britain to take part in a G7 summit. Many public health experts say the U.S. plan falls far short of what’s needed to address the global crisis, which has killed at least 3.7 million people, though public health researchers say the true toll is likely approaching 8 million deaths.

According to the People’s Vaccine Alliance, more than a million COVID deaths have occurred in the past four months, since the leaders of the G7 failed to collectively back a waiver of intellectual property rules for COVID vaccines. The United States now backs the waiver, but other G7 nations and the pharmaceutical industry continue to oppose the waiver.

Based on current vaccination rates, the People’s Vaccine Alliance estimates it could take 57 years to fully vaccinate everyone in low-income nations. The New York Times reports 85% of vaccine doses have gone to people in high- and middle-income countries. On Thursday, the World Health Organization warned, quote, “The threat of a third wave in Africa is real and rising.” Cases are rising in at least 14 African nations over the past two weeks.

In moment, we’ll go to Cape Town to speak with Fatima Hassan, a South African human rights lawyer and HIV/AIDS and social justice activist, founder and director of Health Justice Initiative.

We just had in headlines the World Health Organization warning of a sharp increase in COVID-19 in many parts of Africa, cases rising in at least 14 countries. I want to bring in Fatima Hassen, to talk about what this means, the fact that it is so difficult to get vaccines to the developing world, that it would take something like — what was the estimate? Fifty-seven years?

FATIMA HASSAN: Yeah. Thanks. And I think, you know, the previous speaker is right: We could be addressing this in the next few months, if there was the political will to ensure that many of these front-runner vaccine companies would actually share the knowledge and share the vaccine know-how. In my own country, we’re still waiting for supplies from Johnson & Johnson because of an issue that has arisen in the U.S., and we’re waiting for the FDA clearance. That has halted half of our vaccination program, because we are totally reliant on supplies from two pharmaceutical companies who refuse to issue multiple voluntary licenses, who refuse to allow others to manufacture the vaccines, to share the knowledge and to allow others to be able to be part of the supply chain system.

So, the situation that we have around the number that it will take, the number of years that it will take to vaccinate everybody in the Global South is one of artificial, self-created scarcity. There aren’t enough supplies, because there is knowledge hoarding. And where there are supplies, they’re not coming fast enough. In my own country — it’s June 2021 — we’ve only vaccinated just over 1 million people, half of whom who were part of a study trial. So that tells you there’s something fundamentally wrong with the supply chain system, which is very tenuous in the world at the moment. And despite the WHO saying, you know, in the first half of 2021, let’s at least use available supplies for all healthcare workers around the world or all people over 80, that has not happened. So, you know, I agree there isn’t a prioritization. There’s definitely a scarcity of supplies. But that scarcity can be addressed, and it is self-created.

AMY GOODMAN: So, explain how it could work in South Africa. What would it require of the wealthiest countries, like the United States? I mean, you have the G7 meeting today. That’s the Group of 7: Canada, France, Germany, Italy, Japan, the United Kingdom and the United States. What do you want to see come out of that meeting? What are your demands?

FATIMA HASSAN: So, all of those countries, except the U.S., are actually blocking what we call the TRIPS waiver. (An exception to the Trade-Related Aspects of Intellectual Property Rights).  The U.S. has indicated partial support for the waiver only in relation to vaccine, not in relation to diagnostic technologies or not in relation to therapeutics or other kind of interventions that could actually help us manage the epidemic. For over eight months, the G7 have been sitting on a proposal for the TRIPS waiver that would allow other manufacturers around the world, wherever there is untapped capacity, to be able to make versions of these vaccines so that we can get millions of doses into many different parts of the world. So they’re blocking that, while their own populations are quite advanced in terms of vaccination levels. In some parts of the G7 member states, they’re actually vaccinating younger, healthy people. In my own country, people who are over 80 are still waiting for an appointment for a vaccine.

So, it tells you that the G7 could do a lot more. Many of them have co-invested in some of these vaccines. They actually own the technology. But they’re really fearful. They are deferential to pharmaceutical intellectual property interests. And even with the current state that we’re in, with a number of countries facing a wave three — some may also be facing a wave four — with the hospitalization data that we’re seeing, the morbidity figures that we’re seeing, particularly in Africa, even now countries are still sitting around a table and talking and having long conversations instead of figuring out an urgent way to ramp up manufacturing, scale up production and get as many doses to as many people as possible all over the world.

AMY GOODMAN: I wanted to just share some figures that are pretty astounding. The People’s Vaccine Alliance made calculations with the Health Justice Initiative, Oxfam and UNAIDS. They found last month people living in G7 countries were 77 times more likely to be offered a vaccine than those living in the world’s poorest countries. Between them, G7 nations were vaccinating at a rate of 4.6 million people a day in May. Meanwhile, if this rate continues, everyone living in G7 nations will be fully vaccinated by January. At the current rate, 63,000 people a day, it would take low-income countries 57 years. How many millions of people had to die, Jeffrey Sachs — have to die to make these pharmaceutical drug company billionaires?

JEFFREY SACHS: Let me put it in a somewhat different perspective, if I might. The United States has now vaccinated more than half of the population. Sadly, we have vaccine resistance, which is another tragedy. And I’ll put that aside for the moment. The U.S. has been producing hundreds of millions of doses per month. That is now available for the rest of the world. And that’s why this announcement has been made. But there is no plan of allocation. A similar situation applies in Europe, though Europe is six to eight weeks lagging the United States. A similar situation applies to the U.K., which is also a producing country. China is producing a lot of vaccine now and getting a lot of coverage within China. What it means is that we’re producing globally at a rate maybe of immunizing half a billion people a month. That’s the rate if you add across the companies, roughly. That is plenty of production. But there’s no plan for allocating these vaccines right now. That is unbelievable to this moment.

So, I think the production levels are actually high. They have gone overwhelmingly to the rich countries in the early months, but the rich countries are saturated, essentially, or becoming saturated with coverage, because they have reached, or close to reaching, targets. And that means that this production is available for the world, which needs it urgently, where people are dying without it.

But countries don’t even know a target date right now. They have no idea. They’re completely in the dark. Should they wait for COVAX? Should they go try to sign some agreement with Pfizer at some incredibly marked-up price? Should they make side deals? Should they accept this one or that one? Nobody knows, because there’s no system. And I think that that is largely the fault of the United States and its failure to cooperate transparently and publicly with China, with Russia, with the European producers, with India and with the United Kingdom. In other words, there’s massive supply, but there’s no plan for allocation.

AMY GOODMAN: Final comment, Fatima Hassan, on the issue of the vaccines and what’s happening in South Africa, what’s happening in Uganda, what’s happening in different African countries, what people need to know, on the continent and outside?

FATIMA HASSAN: So, I would say two things. I would slightly disagree: We don’t think the production levels are sufficient, which is why we’re having a supply crisis in almost all of Africa, which also explains why less than 3% of people in Africa have actually received supplies and have actually been vaccinated.

And COVAX is obviously not the solution, even if the U.S. puts in a trickle of 20 million doses into COVAX. COVAX has indicated that by the end of 2021, it’s only likely to cover about 27 to 30% of vulnerable populations in low-income countries. So, COVAX, I think, is a tremendous failure.

The supplies are not sufficient. We don’t believe production levels are enough. And we really need to ramp up manufacturing through the sharing — and urgent sharing — of the vaccine know-how and knowledge. And, you know, the waiver is just one part of that. There now has to be moves for governments, particularly the G7 member states, to compel pharmaceutical companies to share the technology and to transfer the technology, as well.

AMY GOODMAN: Finally, is there concern that the U.S. will be sending, for example, AstraZeneca, when it hasn’t even approved it itself in the United States? And also, the fact that even Moderna and Pfizer vaccines only have emergency use authorization; they haven’t been fully approved. Do you understand the reason for that?

FATIMA HASSAN: So, in relation — 

JEFFREY SACHS:  Oh, I’m sorry.

AMY GOODMAN: Well, let’s go to Fatima, and then I’ll end with Jeffrey Sachs.

FATIMA HASSAN: Sorry, Jeffrey. But in relation to South Africa, Moderna hasn’t even submitted its regulatory dossier. So we wouldn’t, for example, be able to take their supplies right now. They refuse to enter low-income countries. South Africa has taken a decision not to use AstraZeneca. So, at the moment, you know, like I said in the beginning, we’re reliant on Pfizer and Johnson & Johnson. So the issue of vaccine selection in Africa is as equally important. And I think Jeffrey is right. Where is the conversations with Russia and with China? We now know some dossiers from Sputnik, Sinopharm, Sinovac have been submitted. But there seems to be, in some parts of the world, a reluctance to use those vaccines and to rely primarily on vaccines that come from Pfizer and Johnson & Johnson. And that, I think, is going to be our undoing, because certainly don’t have enough supplies of vaccines to go around the world expeditiously.

AMY GOODMAN: Your response, Jeffrey?

JEFFREY SACHS: Just to be clear, I agree on the need for ramping up, but what I’m saying is the reason that Africa has gotten so little, in part, is that the rich countries used all the production in the beginning. And that phase is at an end. It was not an appropriate way to do things. It was the way it was done. Now there is a massive supply that could be brought to bear, and that is the point that I wanted to make. So it’s not a disagreement on what to do. It is a point that we have a massive supply coming available, but without a plan to bring it about.

On the question, should AstraZeneca, should Moderna and others be used, I would say yes. From everything we know about the clinical evidence and the practical efficacy, we need to get comprehensive coverage as rapidly as possible. We are in an unprecedented crisis, but also an unprecedented situation where vaccines have come online for a new disease in a record time. Is there some uncertainty? Yes. But does that merit delay? In my view, absolutely not.

AMY GOODMAN: Well, I want to thank Fatima Hassan, founder and Director of the Health Justice Initiative in South Africa, joining us from Cape Town, and ask Jeffrey Sachs to stay with us after break. I want to ask you about the G7 finance ministers, expected to agree on support for a global minimum corporation tax, and also your criticism of President Biden for backing off of his massive infrastructure plan, what’s being compromised.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to


*American Award-winning investigative journalist and syndicated columnist, author and host/executive producer of Democracy Now!

site admin